New Pricing Deals Pave Way For Piqray & Trodelvy Reimbursement In England
Executive Summary
Health technology assessment body NICE has reversed its previous rejections of Novartis’s Piqray and Gilead’s Trodelvy, both for treating advanced breast cancer. Meanwhile, there are calls to speed up reimbursement decisions for breast cancer drugs.